Crescendo Biologics Strengthens its Management with the Appointment of Dr Pavel Pisa as Chief Medical Officer
Cambridge, UK, 11 September 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel,…
read moreCrescendo Biologics is a clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics based on its unique, patent protected, transgenic mouse platform.
Status current
Associated Fund UK Innovation & Science Seed Fund
Sector Medical / Biotechnology
Website www.crescendobiologics.com
Cambridge, UK, 11 September 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel,…
read moreCollaboration to generate tumor targeting drug conjugates and immuno-oncology therapeutics Crescendo Biologics Limited (Crescendo), the…
read moreCambridge, UK: 2 February 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer…
read moreAntibody veteran joins new CEO as Crescendo redirects strategy to Oncology focus Cambridge, UK: 17…
read more